Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.68) by 44.12 percent. This is a 25.49 percent increase over losses of $(0.51) per share from the same period last year.